These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 26818873)

  • 1. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
    Sosnowski TR
    Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery Technologies for Orally Inhaled Products: an Update.
    Moon C; Smyth HDC; Watts AB; Williams RO
    AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Formulation Development for Inhaled Pharmaceuticals.
    Sou T; Bergström CAS
    J Pharm Sci; 2021 Jan; 110(1):66-86. PubMed ID: 32916138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of inhaled drugs.
    Lipworth BJ
    Br J Clin Pharmacol; 1996 Dec; 42(6):697-705. PubMed ID: 8971424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation Approaches to Overcome Biopharmaceutical Limitations of Inhaled Peptides/Proteins.
    Onoue S; Suzuki H; Seto Y
    Curr Pharm Des; 2015; 21(27):3867-74. PubMed ID: 26290195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route.
    Choudhury H; Gorain B; Chatterjee B; Mandal UK; Sengupta P; Tekade RK
    Curr Pharm Des; 2017; 23(17):2504-2531. PubMed ID: 27908273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems.
    Tayab ZR; Hochhaus G
    Expert Opin Drug Deliv; 2005 May; 2(3):519-32. PubMed ID: 16296772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans.
    Bacle A; Bouzillé G; Bruyère A; Cuggia M; Fardel O; Le Corre P
    Eur J Pharm Biopharm; 2021 Jul; 164():36-53. PubMed ID: 33895293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-Strategies for Improving the Bioavailability of Inhaled Pharmaceutical Formulations.
    Xing Y; Lu P; Xue Z; Liang C; Zhang B; Kebebe D; Liu H; Liu Z
    Mini Rev Med Chem; 2020; 20(13):1258-1271. PubMed ID: 32386491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.
    Tronde A; Nordén B; Marchner H; Wendel AK; Lennernäs H; Bengtsson UH
    J Pharm Sci; 2003 Jun; 92(6):1216-33. PubMed ID: 12761811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism.
    Zhang Z; Gao F; Jiang S; Ma L; Li Y
    Curr Drug Metab; 2012 Oct; 13(8):1110-8. PubMed ID: 22380010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of intranasally delivered peptides: key considerations for pharmaceutical development.
    Al Bakri W; Donovan MD; Cueto M; Wu Y; Orekie C; Yang Z
    Expert Opin Drug Deliv; 2018 Oct; 15(10):991-1005. PubMed ID: 30173579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.